Neuroscience

Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC")…

11 months ago

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,…

11 months ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a…

11 months ago

Banner Health Partners with nference to Accelerate Scientific Discovery for Patient Care

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Banner Health and nference, a science-first software company transforming healthcare by making biomedical data computable, today announced a…

11 months ago

European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,…

11 months ago

Bethany L. Sensenig Joins Supernus’ Board of Directors

ROCKVILLE, Md., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and…

11 months ago

NeuroStar Advanced Therapy Wins 2023 dotCOMM Awards

Award Acknowledges Excellence in Digital Marketing EffortsMALVERN, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical…

11 months ago

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire…

11 months ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown Strathspey Crown did…

11 months ago